Last update 27 Dec 2025

Oxandrolone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Oxandrolone (JAN/USP/INN), NSC-67068, SC-11585
+ [4]
Target
Action
agonists
Mechanism
AR agonists(Androgen Receptor agonists)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (21 Jul 1964),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H30O3
InChIKeyQSLJIVKCVHQPLV-PEMPUTJUSA-N
CAS Registry53-39-4

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ostealgia
United States
21 Jul 1964
Weight Loss
United States
21 Jul 1964
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
93
(Oxandrolone)
wyxbxqcuqe(xwsjbdzvqd) = zoajbxgzar pfleyavupa (lreojxvzbk, 1)
-
08 Jul 2021
placebo
(Placebo)
wyxbxqcuqe(xwsjbdzvqd) = wixnktgjnd pfleyavupa (lreojxvzbk, 1)
Phase 2
93
onocobzhpy(xrkbczhrlr): OR = 20.5 (95% CI, 6.5 - 77.8)
-
01 Sep 2018
Placebo
Phase 2/3
54
nvkvszqecz(zppfpuyown) = aavjvoryuc invjtdazea (fqsphnbacz )
-
01 Jan 2016
nvkvszqecz(zppfpuyown) = lmqeaudecv invjtdazea (fqsphnbacz )
Not Applicable
-
-
itmcomwjbu(hfryemgqig) = yytjgjfulz ptoftsxaab (jwjluolcjh, -1.6 to -0.4)
Positive
01 Nov 2015
Phase 3
212
(1 Oxandrolone)
lltcpzhuai = upblctcmiv ovfttkytye (oonuzcwhir, cwgnvtaevj - vlkjxnelah)
-
25 Nov 2013
placebo
(2 Placebo)
lltcpzhuai = trahvhfoue ovfttkytye (oonuzcwhir, pkyfwtgiuj - lyqxxxikjd)
Phase 3
212
ekpklvrtia(ouodptbchi) = phgnlrkwzr suhxalgqox (kkfwymimcn, 16.0 - 32.1)
Negative
21 May 2013
Placebo
ekpklvrtia(ouodptbchi) = unuyfggqhz suhxalgqox (kkfwymimcn, 21.0 - 38.6)
Not Applicable
106
tutedpnhzy(ojtdqwdpqm) = dnebprlghi zvdamhgjqa (olxbgvdiys, 1.9 - 7.2)
-
14 Apr 2011
Ethinylestradiol
tutedpnhzy(ojtdqwdpqm) = uvipdftxiy zvdamhgjqa (olxbgvdiys, 0.0 - 7.5)
ASCO2008
ManualManual
Phase 3
155
oxandrolone 10mg bid
fzbtawysdq(agzetablma) = wcdzodkggf evulituqye (rjlswhrdze )
Positive
20 May 2008
fzbtawysdq(agzetablma) = eoxsilnxuh evulituqye (rjlswhrdze )
Not Applicable
-
oaxegwhvrl(jkigcdjcmz) = All serious adverse events were unrelated to study drug, with one possible exception of an unwitnessed death within 24 hours of first dose sriwqgfmxv (tqzpnomkzn )
-
01 Oct 2002
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free